The drug vehicle and solvent N-Methylpyrrolidone is an immunomodulator and antimyeloma compound

Jake Shortt, Andy K. Hsu, Benjamin P. Martin, Karen Doggett, Geoffrey M. Matthews, Maria A. Doyle, Jason Ellul, Tina E. Jockel, Daniel M. Andrews, Simon J. Hogg, Andrea Reitsma, David Faulkner, Peter Leif Bergsagel, Marta Chesi, Joan K. Heath, William A. Denny, Philip E. Thompson, Paul J. Neeson, David S. Ritchie, Grant A. McArthurRicky W. Johnstone

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

N-methyl-2-pyrrolidone (NMP) is a common solvent and drug vehicle. We discovered unexpected antineoplastic and immunomodulatory activity of NMP in a cMYC-driven myeloma model. Coincident to this, NMP was identified as an acetyllysine mimetic and candidate bromodomain ligand. Accordingly, NMP-treated cells demonstrated transcriptional overlap with BET-bromodomain inhibition, including downregulation of cMYC and IRF4. NMP's immunomodulatory activity occurred at sub-BET inhibitory concentrations, and, despite phenotypic similarities to lenalidomide, its antimyeloma activity was independent of the IMiD targets cereblon and Ikaros-1/3. Thus, low-affinity yet broad-spectrum bromodomain inhibition by NMP mediates biologically potent, cereblon-independent immunomodulation and at higher doses targets malignant cells directly via BET antagonism. These data reveal that NMP is a functional acetyllysine mimetic with pleotropic antimyeloma and immunomodulatory activities. Our studies highlight the potential therapeutic benefits of NMP, the consequences of current human NMP exposures, and the need for reassessment of scientific literature where NMP was used as an "inert" drug-delivery vehicle.

Original languageEnglish (US)
Pages (from-to)1009-1019
Number of pages11
JournalCell Reports
Volume7
Issue number4
DOIs
StatePublished - May 22 2014

Fingerprint

Immunologic Factors
Pharmaceutical Preparations
Literature
N-methylpyrrolidone
Immunomodulation
Drug delivery
Antineoplastic Agents
Down-Regulation
Cells
Ligands

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Shortt, J., Hsu, A. K., Martin, B. P., Doggett, K., Matthews, G. M., Doyle, M. A., ... Johnstone, R. W. (2014). The drug vehicle and solvent N-Methylpyrrolidone is an immunomodulator and antimyeloma compound. Cell Reports, 7(4), 1009-1019. https://doi.org/10.1016/j.celrep.2014.04.008

The drug vehicle and solvent N-Methylpyrrolidone is an immunomodulator and antimyeloma compound. / Shortt, Jake; Hsu, Andy K.; Martin, Benjamin P.; Doggett, Karen; Matthews, Geoffrey M.; Doyle, Maria A.; Ellul, Jason; Jockel, Tina E.; Andrews, Daniel M.; Hogg, Simon J.; Reitsma, Andrea; Faulkner, David; Bergsagel, Peter Leif; Chesi, Marta; Heath, Joan K.; Denny, William A.; Thompson, Philip E.; Neeson, Paul J.; Ritchie, David S.; McArthur, Grant A.; Johnstone, Ricky W.

In: Cell Reports, Vol. 7, No. 4, 22.05.2014, p. 1009-1019.

Research output: Contribution to journalArticle

Shortt, J, Hsu, AK, Martin, BP, Doggett, K, Matthews, GM, Doyle, MA, Ellul, J, Jockel, TE, Andrews, DM, Hogg, SJ, Reitsma, A, Faulkner, D, Bergsagel, PL, Chesi, M, Heath, JK, Denny, WA, Thompson, PE, Neeson, PJ, Ritchie, DS, McArthur, GA & Johnstone, RW 2014, 'The drug vehicle and solvent N-Methylpyrrolidone is an immunomodulator and antimyeloma compound', Cell Reports, vol. 7, no. 4, pp. 1009-1019. https://doi.org/10.1016/j.celrep.2014.04.008
Shortt J, Hsu AK, Martin BP, Doggett K, Matthews GM, Doyle MA et al. The drug vehicle and solvent N-Methylpyrrolidone is an immunomodulator and antimyeloma compound. Cell Reports. 2014 May 22;7(4):1009-1019. https://doi.org/10.1016/j.celrep.2014.04.008
Shortt, Jake ; Hsu, Andy K. ; Martin, Benjamin P. ; Doggett, Karen ; Matthews, Geoffrey M. ; Doyle, Maria A. ; Ellul, Jason ; Jockel, Tina E. ; Andrews, Daniel M. ; Hogg, Simon J. ; Reitsma, Andrea ; Faulkner, David ; Bergsagel, Peter Leif ; Chesi, Marta ; Heath, Joan K. ; Denny, William A. ; Thompson, Philip E. ; Neeson, Paul J. ; Ritchie, David S. ; McArthur, Grant A. ; Johnstone, Ricky W. / The drug vehicle and solvent N-Methylpyrrolidone is an immunomodulator and antimyeloma compound. In: Cell Reports. 2014 ; Vol. 7, No. 4. pp. 1009-1019.
@article{675f0f6d95dd42c88d2a47758ca4d3c2,
title = "The drug vehicle and solvent N-Methylpyrrolidone is an immunomodulator and antimyeloma compound",
abstract = "N-methyl-2-pyrrolidone (NMP) is a common solvent and drug vehicle. We discovered unexpected antineoplastic and immunomodulatory activity of NMP in a cMYC-driven myeloma model. Coincident to this, NMP was identified as an acetyllysine mimetic and candidate bromodomain ligand. Accordingly, NMP-treated cells demonstrated transcriptional overlap with BET-bromodomain inhibition, including downregulation of cMYC and IRF4. NMP's immunomodulatory activity occurred at sub-BET inhibitory concentrations, and, despite phenotypic similarities to lenalidomide, its antimyeloma activity was independent of the IMiD targets cereblon and Ikaros-1/3. Thus, low-affinity yet broad-spectrum bromodomain inhibition by NMP mediates biologically potent, cereblon-independent immunomodulation and at higher doses targets malignant cells directly via BET antagonism. These data reveal that NMP is a functional acetyllysine mimetic with pleotropic antimyeloma and immunomodulatory activities. Our studies highlight the potential therapeutic benefits of NMP, the consequences of current human NMP exposures, and the need for reassessment of scientific literature where NMP was used as an {"}inert{"} drug-delivery vehicle.",
author = "Jake Shortt and Hsu, {Andy K.} and Martin, {Benjamin P.} and Karen Doggett and Matthews, {Geoffrey M.} and Doyle, {Maria A.} and Jason Ellul and Jockel, {Tina E.} and Andrews, {Daniel M.} and Hogg, {Simon J.} and Andrea Reitsma and David Faulkner and Bergsagel, {Peter Leif} and Marta Chesi and Heath, {Joan K.} and Denny, {William A.} and Thompson, {Philip E.} and Neeson, {Paul J.} and Ritchie, {David S.} and McArthur, {Grant A.} and Johnstone, {Ricky W.}",
year = "2014",
month = "5",
day = "22",
doi = "10.1016/j.celrep.2014.04.008",
language = "English (US)",
volume = "7",
pages = "1009--1019",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - The drug vehicle and solvent N-Methylpyrrolidone is an immunomodulator and antimyeloma compound

AU - Shortt, Jake

AU - Hsu, Andy K.

AU - Martin, Benjamin P.

AU - Doggett, Karen

AU - Matthews, Geoffrey M.

AU - Doyle, Maria A.

AU - Ellul, Jason

AU - Jockel, Tina E.

AU - Andrews, Daniel M.

AU - Hogg, Simon J.

AU - Reitsma, Andrea

AU - Faulkner, David

AU - Bergsagel, Peter Leif

AU - Chesi, Marta

AU - Heath, Joan K.

AU - Denny, William A.

AU - Thompson, Philip E.

AU - Neeson, Paul J.

AU - Ritchie, David S.

AU - McArthur, Grant A.

AU - Johnstone, Ricky W.

PY - 2014/5/22

Y1 - 2014/5/22

N2 - N-methyl-2-pyrrolidone (NMP) is a common solvent and drug vehicle. We discovered unexpected antineoplastic and immunomodulatory activity of NMP in a cMYC-driven myeloma model. Coincident to this, NMP was identified as an acetyllysine mimetic and candidate bromodomain ligand. Accordingly, NMP-treated cells demonstrated transcriptional overlap with BET-bromodomain inhibition, including downregulation of cMYC and IRF4. NMP's immunomodulatory activity occurred at sub-BET inhibitory concentrations, and, despite phenotypic similarities to lenalidomide, its antimyeloma activity was independent of the IMiD targets cereblon and Ikaros-1/3. Thus, low-affinity yet broad-spectrum bromodomain inhibition by NMP mediates biologically potent, cereblon-independent immunomodulation and at higher doses targets malignant cells directly via BET antagonism. These data reveal that NMP is a functional acetyllysine mimetic with pleotropic antimyeloma and immunomodulatory activities. Our studies highlight the potential therapeutic benefits of NMP, the consequences of current human NMP exposures, and the need for reassessment of scientific literature where NMP was used as an "inert" drug-delivery vehicle.

AB - N-methyl-2-pyrrolidone (NMP) is a common solvent and drug vehicle. We discovered unexpected antineoplastic and immunomodulatory activity of NMP in a cMYC-driven myeloma model. Coincident to this, NMP was identified as an acetyllysine mimetic and candidate bromodomain ligand. Accordingly, NMP-treated cells demonstrated transcriptional overlap with BET-bromodomain inhibition, including downregulation of cMYC and IRF4. NMP's immunomodulatory activity occurred at sub-BET inhibitory concentrations, and, despite phenotypic similarities to lenalidomide, its antimyeloma activity was independent of the IMiD targets cereblon and Ikaros-1/3. Thus, low-affinity yet broad-spectrum bromodomain inhibition by NMP mediates biologically potent, cereblon-independent immunomodulation and at higher doses targets malignant cells directly via BET antagonism. These data reveal that NMP is a functional acetyllysine mimetic with pleotropic antimyeloma and immunomodulatory activities. Our studies highlight the potential therapeutic benefits of NMP, the consequences of current human NMP exposures, and the need for reassessment of scientific literature where NMP was used as an "inert" drug-delivery vehicle.

UR - http://www.scopus.com/inward/record.url?scp=84901248465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901248465&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2014.04.008

DO - 10.1016/j.celrep.2014.04.008

M3 - Article

C2 - 24813887

AN - SCOPUS:84901248465

VL - 7

SP - 1009

EP - 1019

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 4

ER -